Note: This announcement is modified to include a period of performance. The upcoming award will include a 12 month base period from the date of award, plus a one year option period. The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics Branch (DCEG), plans to procure on a sole source basis a collaborative contract to: 1) collect common clinical data and biospecimens to permit statistically robust studies; 2) identify the contribution of germline TP53 mutations to mitochondrial function, and determine if abnormal mitochondrial function is a marker of cancer risk; (3) conduct a pilot study of diet and physical activity data collection in this high-risk setting, as a first step towards a formal intervention study; and 4) determine the role of telomere biology as a cancer risk modifier, with Fundao Antonio Prudente, Hospital A C Camargo, S'o Paulo, Brazil This acquisition will be processed in accordance with simplified acquisitions procedures as stated in FAR Part 13 13.106-1(b)(1) and is exempt for the requirements of FAR Part 6. The North American Industry Classification System code is 518210 and the business size standard is $30.0 million. Only one award will be made as a result of this solicitation. The contract will be awarded as a firm fixed price type contract. In addition, the award will be for one year only; however, the exact period of performance has not been determined at this time. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome in which the age at cancer onset ranges from newborn to old age. Approximately 70% of individuals fitting classical diagnostic criteria have germline mutations in the p53 gene (TP53). Mutation carriers have an 80-100% chance of developing cancer prior to age 60. The p53 protein is a key component in many critical cellular functions, including apoptosis, cell cycle, senescence, DNA repair, energy metabolism and mitochondrial function. The p53 protein regulates mitochondrial oxygen utilization, reactive oxygen species (ROS) generation, and disposition of ROS. Early data suggest the presence of mitochondrial dysfunction and short telomeres in mutation carriers. This procurement is required for the collaborative effort, designed and led by NCI, between the CGB, NCI and Hospital A. C. Carmargo-Fundao Antonio Prudente, S'o Paulo, Brazil which will: 1) collect common clinical data and biospecimens to permit statistically robust studies; 2) identify the contribution of germline TP53 mutations to mitochondrial function, and determine if abnormal mitochondrial function is a marker of cancer risk; (3) conduct a pilot study of diet and physical activity data collection in this high-risk setting, as a first step towards a formal intervention study; and 4) determine the role of telomere biology as a cancer risk modifier. These studies will lead to better risk stratification of patients with LFS, and advance understanding of the consequences of a germline TP53 mutation, findings that may also be broadly applicable to sporadic cancers of the type seen in LFS. The requested scope of the work can only be reasonably achieved through the collaborative efforts of the Hospital A. C. Camargo - Fundao Antonio Prudente and the NCI. The LFS patient population at Hospital A. C. Camargo - Fundao Antonio Prudente is unique and not readily available elsewhere. Studies of LFS in Southern Brazil have identified a unique cohort of patients with a founder mutation (TP53*R337H) in approximately 0.3% of newborns. This is not a solicitation for competitive quotations. However, if any interested party especially small business, believes they can meet the above requirement, they may submit a capability statement, proposal, or quotation which will be considered by the agency. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. Responses must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on, August 20, 2014. All responses and questions must be in writing and can be faxed
+1 (555) 000-0000 or emailed to Gwennifer Epps, Contracting Officer at
contact@example.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02CP42600-83 on all correspondence.
